J&J leukemia drug cuts death risk vs. chemo in new patients: study

(Reuters) - Johnson & Johnson's and AbbVie's cancer drug Imbruvica significantly reduced the risk of death and disease progression compared with chemotherapy in previously untreated patients with a type of leukemia in a late stage study, paving the way for an expanded approval of the medicine.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro